SQUAMOUS NON-SMALL-CELL LUNG CANCER
Clinical trials for SQUAMOUS NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new SQUAMOUS NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for SQUAMOUS NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double immunotherapy attack shows promise for tough lung cancer
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Custom-Made vaccine takes on tough cancers in early trial
Disease control TerminatedThis early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo shows promise for Tough-to-Treat cancers
Disease control OngoingThis study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug shows promise for Hard-to-Treat lung cancer
Disease control OngoingThis early-phase trial tests a drug called HER3-DXd in people with advanced non-small cell lung cancer that has spread or cannot be removed by surgery. The study includes patients with specific genetic changes (EGFR or KRAS mutations) whose cancer worsened after other treatments.…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
AI-Designed vaccine takes on lung cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…
Matched conditions: SQUAMOUS NON-SMALL-CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC